Fortress Biotech, Inc. — Director's Dealing 2019

Jul 19, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Fortress Biotech, Inc. (FBIO)
CIK: 0001429260
Period of Report: 2019-07-18

Reporting Person: ROSENWALD LINDSAY A MD (Director, PRESIDENT, CEO & CHAIRMAN, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-07-18	COMMON STOCK, PAR VALUE $0.001	A	396825	$1.26	Acquired	8569722	Direct

Footnotes

F1: Shares acquired as a result of prepayment of debt owed to Dr. Rosenwald that was held in the name of Opus Point Healthcare Innovations Fund, LP ("Opus"), an investment fund co-owned by Dr. Rosenwald, in the form of the Company's common stock (measured at the closing price on July 18, 2019), under that certain Amended & Restated Credit Facility Agreement, dated as of March 12, 2018, by and between the Company and Opus.